文献速递淋巴瘤造血干细胞移植与细胞治疗

利妥昔单抗治疗失败与DLBCL型移植后淋巴增殖性疾病不良预后相关

Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder.
PubMed 文献 · Br J Haematol · 2020-02-18

R-CHOP与R-primary策略间OS无差异;在109例R-primary患者中,基线IPI评分和R诱导反应预测OS,R诱导失败者接受R-CHOP仅 marginally 改善2年OS(45% vs 32%)。

要点

  • R-CHOP与R-primary策略在OS上无差异。
  • R诱导失败和高IPI评分提示预后不良。

核心结论

  • 在真实世界DLBCL型PTLD患者中,利妥昔单抗诱导失败和高IPI评分预测不良结局。

研究设计与样本

  • 多中心回顾性队列研究,纳入168例接受利妥昔单抗治疗的实体器官移植后DLBCL型PTLD成人患者。

主要发现

  • R-CHOP与R-primary策略之间未观察到OS差异。
  • 109例R-primary患者中,多因素分析显示基线IPI评分和R诱导反应预测OS。

关键数值与推荐

  • R诱导失败定义为R诱导后疾病稳定或进展。
  • R-primary策略类似PTLD-1临床试验,包括四剂每周利妥昔单抗诱导,无化疗或后续R-CHOP。

临床怎么用

  • 对DLBCL型PTLD患者,可考虑利妥昔单抗为基础的治疗策略。
  • R诱导失败且高IPI评分者预后差,需密切监测和个体化治疗决策。

局限性

  • 回顾性研究设计可能引入选择偏倚。
  • 样本量有限,尤其R诱导失败亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Post-transplant lymphoproliferative disorder (PTLD) may arise after solid organ transplantation, and the most common subtype resembles diffuse large B cell lymphoma (DLBCL). In DLBCL-type PTLD, the anti-CD20 antibody rituximab (R) may be combined with chemotherapy (R-CHOP) or use a strategy (R-primary; similar to the PTLD-1 clinical trial) consisting of induction with four weekly doses of R-alone, without any chemotherapy or sequential R-CHOP follow-up. Here we report on a multicentre retrospective cohort of solid organ transplant patients with DLBCL-type PTLD that were treated with R. In 168 adults, two-year overall survival (OS) was 63·7% [95% CI (confidence interval) 56·6-71·7%]. No difference in OS was observed, whether patients were treated with R-CHOP versus the R-primary strategy. In the 109 patients treated with R-primary, multivariate analysis found that baseline IPI score and the response to R-induction predicted OS. Patients who responded to R-induction had durable remissions without the addition of chemotherapy. Conversely, of the 46 patients who had stable or progressive disease after R-induction (R-failure), those who received R-CHOP had an only marginally improved outcome, with a two-year OS of 45% (23·1-65·3%) vs. no R-CHOP at 32% (14·7-49·8%). In real-world patients, R-failure and high IPI scores predict a poor outcome in DLBCL-type PTLD.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Jain MD, Lam R, Liu Z, et al. Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder. Br J Haematol. 2020. PMID: 32068243. doi:10.1111/bjh.16304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。